Showing results (51-60 of 259) with videos related to
Sort By:
Pageof 26
Biomedicines|March 25, 2022
Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?Giorgio Maria Saracco, Alfredo Marzano, Mario RizzettoHepatology International|July 24, 2015
Multiple courses of G-CSF in patients with decompensated cirrhosis: consistent mobilization of immature cells expressing hepatocyte markers and exploratory clinical evaluationSilvia Gaia, Antonella Olivero, Antonina Smedile, et al.Hepatology (Baltimore, Md.)|September 26, 2002
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapyGiorgio Saracco, Alda Olivero, Alessia Ciancio, et al.Antiviral Research|June 24, 2014
Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent mannerAmedeo De Nicolò, Lucio Boglione, Alessia Ciancio, et al.The Lancet. Infectious Diseases|March 21, 2008
Helicobacter species and liver diseases: association or causation?Rinaldo Pellicano, Armelle Ménard, Mario Rizzetto, et al.Transplantation|April 11, 2022
Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected RecipientsSilvia Martini, Francesco Tandoi, Renato Romagnoli, et al.Critical Reviews in Microbiology|November 26, 2003
Helicobacter pylori and coronary heart disease: which directions for future studies?Rinaldo Pellicano, Sharmila Fagoonee, Mario Rizzetto, et al.Journal of Viral Hepatitis|October 11, 2025
Applying the COM-B Model to Identify Barriers to Bulevirtide Adherence in Chronic Hepatitis D: A Multicenter Italian StudyLorenzo Badia, Alessia Ciancio, Marco Distefano, et al.Therapeutic Drug Monitoring|March 13, 2012
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatmentAntonio DʼAvolio, Alessia Ciancio, Marco Siccardi, et al.Antiviral Therapy|May 12, 2009
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological responseStefan Zeuzem, Mario Rizzetto, Peter Ferenci, et al.Pageof 26